S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
S&P 500   4,486.46 (+0.34%)
DOW   35,258.61 (-0.10%)
QQQ   372.65 (+1.01%)
AAPL   146.55 (+1.18%)
MSFT   307.29 (+1.01%)
FB   335.34 (+3.26%)
GOOGL   2,855.56 (+1.00%)
TSLA   870.11 (+3.21%)
AMZN   3,446.74 (+1.11%)
NVDA   222.22 (+1.65%)
BABA   166.82 (-0.70%)
NIO   39.61 (+5.04%)
CGC   13.20 (-1.12%)
GE   104.12 (-0.28%)
AMD   116.43 (+3.84%)
MU   67.26 (-0.62%)
T   25.33 (-1.44%)
F   15.56 (-0.89%)
ACB   6.92 (-1.56%)
DIS   171.14 (-3.01%)
PFE   41.32 (-0.41%)
BA   216.98 (-0.03%)
AMC   43.03 (+5.62%)
NASDAQ:FEMY

Femasys Stock Forecast, Price & News

$6.99
-0.01 (-0.14 %)
(As of 10/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.98
$7.08
50-Day Range
$6.52
$7.96
52-Week Range
$6.50
$13.75
Volume7,641 shs
Average Volume118,510 shs
Market Capitalization$82.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FEMY News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.


About Femasys

Femasys Inc., a biomedical company, researches, develops, and manufactures medical devices for the women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a sterile, single-use disposable endocervical curettage product; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FEMY
Employees
25
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$82.48 million
Next Earnings Date
11/10/2021 (Estimated)
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.50 out of 5 stars

Medical Sector

1056th out of 1,361 stocks

Surgical & Medical Instruments Industry

104th out of 124 stocks

Analyst Opinion: 3.5Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Femasys (NASDAQ:FEMY) Frequently Asked Questions

Is Femasys a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Femasys stock.
View analyst ratings for Femasys
or view top-rated stocks.

What stocks does MarketBeat like better than Femasys?

Wall Street analysts have given Femasys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Femasys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Femasys?

Femasys saw a increase in short interest in September. As of September 30th, there was short interest totaling 18,900 shares, an increase of 293.8% from the September 15th total of 4,800 shares. Based on an average trading volume of 77,400 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.3% of the shares of the stock are sold short.
View Femasys' Short Interest
.

When is Femasys' next earnings date?

Femasys is scheduled to release its next quarterly earnings announcement on Wednesday, November 10th 2021.
View our earnings forecast for Femasys
.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) posted its quarterly earnings data on Wednesday, August, 11th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.25) by $0.27. The company had revenue of $0.33 million for the quarter.
View Femasys' earnings history
.

What price target have analysts set for FEMY?

2 brokers have issued twelve-month target prices for Femasys' shares. Their forecasts range from $8.45 to $25.00. On average, they anticipate Femasys' share price to reach $16.73 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price.
View analysts' price targets for Femasys
or view top-rated stocks among Wall Street analysts.

Who are Femasys' key executives?

Femasys' management team includes the following people:
  • Ms. Kathy Lee-Sepsick, Founder, Chairman, CEO & Pres (Age 54, Pay $306.54k)
  • Mr. Daniel Scott Currie, SVP of Operations & Sec. (Age 57, Pay $225.63k)
  • Mr. Gary Thompson, CFO & VP of Fin. & Admin. (Age 64)
  • Ms. Mary An Merchant J.D., Ph.D., VP of Counsel & Intellectual Property
  • Mr. Steven P. Damon, VP of Bus. Devel. (Age 65)
  • Mr. Todd A. Creech, Chief Financial Advisor (Age 53)
  • Dr. Jeffrey Marcus M.D., M.S., Chief Medical Advisor

When did Femasys IPO?

(FEMY) raised $35 million in an initial public offering on Friday, June 18th 2021. The company issued 2,700,000 shares at $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.

What is Femasys' stock symbol?

Femasys trades on the NASDAQ under the ticker symbol "FEMY."

When does Femasys' lock-up period expire?

Femasys' lock-up period expires on Wednesday, December 15th. Femasys had issued 2,650,000 shares in its IPO on June 18th. The total size of the offering was $34,450,000 based on an initial share price of $13.00. After the end of Femasys' lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Who are Femasys' major shareholders?

Femasys' stock is owned by a number of retail and institutional investors. Top institutional investors include Clear Creek Financial Management LLC (0.20%).
View institutional ownership trends for Femasys
.

Which institutional investors are buying Femasys stock?

FEMY stock was purchased by a variety of institutional investors in the last quarter, including Clear Creek Financial Management LLC.
View insider buying and selling activity for Femasys
or or view top insider-buying stocks.

How do I buy shares of Femasys?

Shares of FEMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Femasys' stock price today?

One share of FEMY stock can currently be purchased for approximately $6.99.

How much money does Femasys make?

Femasys has a market capitalization of $82.48 million.

How many employees does Femasys have?

Femasys employs 25 workers across the globe.

What is Femasys' official website?

The official website for Femasys is www.femasys.com.

How can I contact Femasys?

The company can be reached via phone at 770-500-3910 or via email at [email protected].


This page was last updated on 10/18/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.